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Systemic sclerosis (SSc) is characterized by tissue ﬁbrosis, vasculopathy and autoimmunity. Indoleamine
2,3 dioxygenase (IDO) plays a pivotal role in immunological tolerance modulating regulatory T cell (Treg)
generation and function. Single nucleotide polymorphisms (SNPs) of IDO gene could impact on Treg func-
tion and predispose to autoimmunity. Here, the existence of an association between speciﬁc IDO SNPs
and SSc was analyzed.
Five speciﬁc SNPs in IDO gene were searched in 31 SSc patients and 37 healthy controls by gene
sequencing or restriction fragment length polymorphism. The function of both CD4+CD25+ and CD8+
Treg from SSc patients was analyzed by proliferation suppression assay.
SNP rs7820268 was statistically more frequent in SSc patients than in controls. Notably, SSc patients
bearing the T allelic variant of the rs7820268 SNP showed impaired CD8+ Treg function.
Our unprecedented data show that a speciﬁc IDO gene SNP is associated with an autoimmune disease
such as SSc.
 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights
reserved.1. Introduction
Systemic sclerosis (SSc) is a connective tissue disease character-
ized by immune alterations, vasculopathy and ﬁbrosis [1].
Although SSc pathogenesis is poorly deﬁned, autoimmunity seems
to play an important role as demonstrated by the presence of cir-
culating autoantibodies and activated T cells inﬁltrating diseased
tissues [1,2]. Genetic predisposition to the disease has been postu-
lated on the basis of epidemiologic evidences and supported by the
discovery of mutations/polymorphisms affecting different genes
related to the connective tissue, the vascular system as well as
the immune system [3]. Recently, the existence of an unbalance
between Th17 pro-inﬂammatory responses and regulatory T lym-
phocyte (Treg) function has been highlighted, suggesting that the
impairment of the Treg compartment could play role in SSc patho-
genesis as already shown for other autoimmune diseases [4,5].n Society for Histocompatibility an
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the enzyme indoleamine 2,3-dioxygenase (IDO) is mainly at play.
Indeed, IDO, leading to kynurenine production through tryptophan
degradation, suppresses effector T cell function and favors the dif-
ferentiation of Treg [6–11]. Genetic variants of the IDO gene may
modify IDO activity [12] potentially predisposing to immune alter-
ations and/or autoimmunity. Whether genetic variants of IDO gene
may be present in SSc patients has not been investigated. Here, the
association of speciﬁc single nucleotide polymorphisms (SNPs) of
IDO gene with SSc was analyzed taking also into account Treg func-
tional activity in individual SSc patients.2. Material and methods
2.1. Patients and controls
Thirty-one patients affected with SSc (mean age 64 ± 11 years,
female/male ratio 7/1) were enrolled at the Division of Internal
Medicine and Clinical Immunology of the Department of Internal
Medicine, University of Genoa, after giving their informed consent.
Diagnosis of SSc was made according to the American College of
Rheumatology criteria [13] and median disease duration was
17 ± 13 years. Patients were subdivided as having limited (lSSc,
25 patients) or diffuse (dSSc, 6 patients) SSc and were underd Immunogenetics. Published by Elsevier Inc. All rights reserved.
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channel blockers) but not with immunosuppressive drugs [14].
Thirty seven healthy subjects, age and sex matched with the SSc
patients, were studied as controls.
The study was approved by the Ethical Committee of San Mar-
tino Hospital in Genoa.
2.2. Gene sequencing
Genomic DNA was extracted from 300 ll of peripheral blood in
sodium citrate using the Puregene Dna puriﬁcation system (GEN-
TRA System, MN). Primers were designed to amplify the exons 1,
3 and 5 as well as the introns 5 and 6 (chromosome 8,
39777452-39777758; BLAST NCBI Genome Browser) of IDO gene
(GenBank ID: NG_028155). Gene ampliﬁcation was performed by
polymerase chain reaction (PCR) using 1.5 nM Mg2+ concentration
and different annealing temperatures (Table 1). PCR products of
exons 1 and 5 as well as of introns 5 and 6 were then puriﬁed by
UltraClean PCR clean up Sample Kit (QIAGEN, Hilden, Germany),
sequenced using the ABI BigDye Terminator (Applied Biosystems,
Foster City, CA), and then run on an ABI 3130XL Genetic Analyzer
machine (Applied Biosystems, Foster City, CA). Chromatogram
analysis was performed by Chromas Software (Technelysium Pty
Ltd., Helensvale, Au). Each sample was compared with the IDO
gene sequence present in NCBI database by Lasergene SeqMan
Software (DNASTAR, Madison, USA).
2.3. Genotyping analysis by restriction fragment length polymorphism
The rs35099072 SNP in exon 3, located within the restriction
site of HAEIII, was searched by restriction fragment length
polymorphism. Ten to twenty micro litre of the corresponding PCR
product were digested using the Fastdigest HaeIII restriction en-
zyme (FERMENTAS - Thermo/Fisher Scientiﬁc Company -Waltham,
Massachusetts, USA) following manufacturer’s recommendations.
Allelic discrimination was performed running digested DNA on a
2% agarose electrophoresis.
2.4. Generation of CD8+ Treg
CD8+ Treg were generated as described [15]. Peripheral blood
mononuclear cells (PBMC) were puriﬁed by centrifugation on Ficoll
gradient. CD8+CD28 T cells were sorted using magnetic micro-
beads conjugated with speciﬁc monoclonal antibodies (mAb) (Life
Technologies - Carlbad, USA). The purity of sorted cells was P95%
as demonstrated by ﬂow cytometric analysis. Puriﬁed CD8+CD28
T lymphocytes were cultured in complete culture medium RPMI
1640 with 20 U/ml of IL2 (Proleukin, Eurocetus, BV) and 20 ng/ml
of IL10 (R&D System, MN USA) for 7 days. At the end of the incuba-
tion the cells were used as suppressors in a proliferation suppres-
sion assay.
2.5. Puriﬁcation of CD4+CD25hi Treg
CD4+CD25hi Treg were puriﬁed from PBMC by magnetic bead
cell sorting using the CD4+CD25hi human regulatory T cell isolation
kit (Miltenyi Biotech, Bergisch Gladbach, Germany). The purity ofTable 1
Primers and temperatures used for PCR ampliﬁcations.
Exon Intron Forward primer 50-30
1 CTCACTGCCCCTGTGATAAAC
3 AGAGTAGTCAGGAGGATT
5 5–6 TGTAATGCCTACTGAAGAAACsorted cells was P95% as demonstrated by ﬂow cytometric
analysis.2.6. Immunoﬂuorescence analyses
Phenotypes were analyzed by immunoﬂuorescence incubating
the cells (1  105 cells in 100 ll of PBS) with speciﬁc mAbs at
4 C for 30 min in the dark. The following mAbs were used: phyco-
erythrin (PE) conjugated anti-CD127, allophycocianin (APC)-cyanin
(Cy) 7-conjugated anti-CD3 (e-Biosciences, San Diego, CA), PE and
ﬂuorescein isothiocynate (FITC) conjugated anti-CD25 (Miltenyi,
Bergisch Gladbach, Germany), Pe-Cy7-conjugated anti-CD8
(Biolegend, San Diego, CA), Peridin-Chlorophyll-protein complex
(PerCP)-Cy5.5-conjugated anti-CD28 (eBioscience, San Diego, CA).
Then the cells were analyzed by a FACSCanto II ﬂow cytometer
(BD Biosciences, Franklin Lakes, New Jersey) using FACSDIVA soft-
ware (BD Biosciences, Franklin Lakes, New Jersey).2.7. Proliferation suppression assay
The suppressive activity of Treg was evaluated by monitoring
the inhibition of dye dilution in PBMC stained with Carboxyﬂuo-
rescein diacetate succinimidyl ester (CFDA-SE) (5 lM) (Molecular
Probes, Life Technologies, Carlbad, USA) before the test. Thereafter,
the cells were pulsed with the anti-CD3 UCHT-1 mAb (5 lg/ml)
(BD Bioscience, Franklin Lakes, New Jersey) and cultured for 5 days
in 96 well ﬂat bottomed plates (1  105 cells/well) in the presence
(or not) of CD8+ or CD4+CD25hi Treg (1  105 cells/well). After
washings the samples were analyzed by ﬂow cytometer excluding
dead cells from analysis by adding 7-amino-actinomycin D (7AAD)
(BD Bioscience, Franklin Lakes, New Jersey) before acquisition.2.8. Statistical analysis
Statistically signiﬁcant differences between frequencies were
assessed using the Chi-square test for binary variables. Analyses
were performed using GraphPad Prism 5 software (GraphPad Soft-
ware, San Diego – California, USA).3. Results
3.1. The frequency of rs7820268 (C6202T) SNP is increased in
scleroderma patients compared with controls
The following SNPs of IDO gene, already described in the
general population (Gene Sorter, NCBI Genome Browser), were
comparatively analyzed in SSc patients and healthy controls:
rs35059413 (C123T) in exon 1, rs35099072 (C4325T) in exon 3,
rs61753677 (C6293T) in exon 5, rs7820268 (C6202T) in intron 5
and rs73619577 (C6982A) in intron 6.
Concerning the rs7820268 SNP, the genotypes carrying the T
allelic variant (C/T + T/T), together considered, were signiﬁcantly
more frequent in SSc patients than in healthy donors (Table 2).
Accordingly, the frequency of the T variant allele was signiﬁcantly
higher in the studied SSc population than in control group





Frequencies of genotypes carrying the rs7820268 SNP T allelic variant in SSc patients
and controls.
SSc patients Controls Odds ratio 95% conﬁdence intervals P value
22/31 17/37 2.876 1.047-7.895 0.03
Chi-square test comparing the frequency of C/T + T/T genotypes in 31 SSc patients
and 37 healthy controls was performed.
Table 3
Frequencies of rs7820268 SNP T allele in SSc patients and controls.
SSc patients Controls Odds ratio 95% conﬁdence intervals P value
27/62 18/74 2.400 1.155-4.985 0.01
Chi-square test comparing the frequency of the T allele in 31 SSc patients and 37
healthy controls was performed.
Table 4
CD8+ Treg suppression activity in SSc patients carrying or not the rs7820268 SNP T
allele.
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rs35059413, rs35099072, rs61753677 and rs73619577 SNPs were
not detected.
No statistically signiﬁcant associations were detected between
the frequency of rs7820268 (C6202T) SNP and independent vari-
ables such as age, sex, disease form, and speciﬁc clinical features
typical of SSc, analyzed by a panel of clinical tests routinely applied
in our center to SSc patients [16], including: frequency/intensity of
Raynaud phenomenon as well microvessel abnormalities (mea-
sured by nailfold videocapillaroscopy), skin ﬁbrosis (measured by
mRodnan score and by plicometry) [17], lung alterations (analyzed
by spirometry), esophagous abnormalities (analyzed by pH-metry
and manometry), renal dysfunction (tested by dosing serum creat-
inine levels and measuring the intrarenal resistive index by duplex
doppler sonography), heart disease (evaluated by echocardiogra-
phy) (not shown).3.2. Alteration of CD8+ Treg function is present in patients bearing the
rs7820268 (C6202T) SNP
The suppressive functions of CD4+CD25hi or CD8+ Treg were
comparatively analyzed in SSc patients carrying or not the T allelic
variant of the rs7820268 SNP.
A suppression activity P25% was considered as normal since
comparable to that of healthy controls [4,18]. Impaired suppres-
sion activity of CD8+ Treg was observed in 5/11 (45%) of SSc pa-
tients carrying the T allelic variant, and in any of SSc patients
with the corresponding C allelic variant (Fig. 1 and Table 4). Con-
cerning this parameter, no differences were observed betweenFig. 1. Frequency of SSc patients carrying the rs7820268 T allelic variant showing altere
Treg from SSc patients carrying either the C allelic variant in homozygosis or the T all
considered as normal since comparable to that of healthy controls. Black boxes relate to p
with a <25% CD8+ Treg suppression activity. A Chi-square test analysis was performedhomozygous and heterozygous SSc patients for the rs7820268
SNP T allele (not shown).
No statistically signiﬁcant difference of CD4+CD25hi Treg func-
tion was detected between SSc patients carrying or not the T allelic
variant (data not shown).4. Discussion
The results of this study show that the T allelic variant of the
IDO gene rs7820268 SNP: (a) is signiﬁcantly more frequent in
SSc patients than in healthy controls; (b) may be associated with
impaired CD8+ Treg suppression activity.
IDO is highly involved in maintenance of immunologic homeo-
stasis since its activation inhibit effector/inﬂammatory T cells and
promote the differentiation and activation of Treg [6–11]. Interest-
ingly, Treg alterations have been recently demonstrated in SSc pa-
tients [4] and IDO itself seems to be related to different
pathological conditions such as autoimmunity, allergy, chronic
inﬂammation and tumors [19–21].
Although polymorphisms of IDO gene have been observed in
the general population [12], no data exist on their possible associ-
ation with speciﬁc diseases. Here it is reported the unprecedented
ﬁnding of an IDO gene SNP, rs7820268, that appears to be associ-
ated with SSc. Notably, the fact that a nucleotidic substitution,d CD8+ Treg function. Proliferation suppression assays were performed with CD8+
elic variant in homozygosis or in heterozygosis. A suppression activity P25% was
atients with aP25% CD8+ Treg suppression activity; white boxes relate to patients
and the statistically signiﬁcant difference is indicated.
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a gene product is not surprising since it may affect mRNA splicing
or speciﬁc regulatory sequence(s) modulating gene expression
[22].
When the SSc population was comparatively analyzed in rela-
tion to the presence of the T or the C rs7820268 SNP allelic variants,
alterations of Treg function, targeting speciﬁcally the CD8+ Treg,
were observed only in SSc patients carrying the T allelic variant.
This ﬁnding suggests that this IDO allele might effectively impact
on Treg-controlled immunological regulatory circuits. Interest-
ingly, IDO is not expressed by the subpopulation of CD8+ Treg
(namely, non-antigen speciﬁc CD8+ Treg [15]) on which we focused
our study (our unpublished observation). Hence, it is likely that
rs7820268 SNP affects IDO expression or function in cell popula-
tions different from Treg (i.e. in dendritic cells) and that such event
may have an effect on the cell-to-cell crosstalk leading to CD8+ (but
not CD4+CD25hi) Treg generation. The validity of this hypothesis as
well as the predictive/prognostic relevance of the analysis of
rs7820268 SNP in SSc will be addressed by a new study involving
a larger SSc population.
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